AlphAIAlphAI — Financial news for AI agents
fool.comSEP 292 min read$DVA

This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.

Berkshire Hathaway, led by Warren Buffett, owns 28 million shares of DaVita (DVA), worth $5.18 billion. DaVita's stock is up 58% this year. Berkshire has been reducing its stake, selling over 1.2 million shares in recent quarters. DaVita's aggressive share buybacks have increased Berkshire's ownership to over 45%. DaVita reported $3.55 billion in Q2 revenue and $4.02 EPS, up 55% year-over-year.

Original reporting
fool.com
Published Sep 29, 2026, 9:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 10:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next. — source image
Source · fool.com
Decision brief

The 30-second read

$DVABearishLow
01

Why it matters

Berkshire's incremental sales provide a tangible catalyst that could temper DaVita's rally, offering a short‑term trading angle.

02

Market read

The news is relevant for traders monitoring large‑cap shareholder actions and their effect on mid‑cap healthcare stocks.

03

What to watch

DaVita's strong earnings growth and market share gains could offset the impact of Berkshire's stake reduction.

Relevance 4/10Novelty 2/10Timing: post‑market commentary

Background

The article discusses Berkshire Hathaway's historical and recent reduction of its DaVita holdings as the stock climbs 58% YTD.

Company-level read

Ticker impact

$DVABearishHigh confidence
Context

Berkshire Hathaway has been selling DaVita shares in Q1 and Q2 2026, reducing its stake as the stock rallies.

Expected impact

likely downward pressure as the market prices in Berkshire's incremental sell‑off

Evidence & confidence

Berkshire's large stake and its recent sales are a concrete catalyst that can move the stock.

Market effects

Sector

Potential short‑term drag on the healthcare sector as a major shareholder reduces exposure.

Regional

Limited to U.S. markets where DaVita trades.

Global

Minimal global impact beyond investors tracking Berkshire's moves.

Counterpoint

What could challenge this read

Berkshire's sales may be strategic profit‑taking; the stock could resume its uptrend once the sell‑off subsides.

Key entities

  • Investor
    Berkshire Hathaway

    Large shareholder reducing its DaVita position.

  • Company
    DaVita Inc.

    Healthcare provider whose stock has risen sharply.

Read at source← All news

Related articles

AUG 27
$DVAMedAI 8/10

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

fool.com2 min
AUG 8
$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

yahoo.com5 min
AUG 7
$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

investing.com3 min
AUG 6
$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

yahoo.com7 min